Quoin Pharmaceuticals Releases Second Episode of its "Living with Netherton" Series, as part of its ongoing NETHERTON NOW awareness campaign

Core Insights - Quoin Pharmaceuticals has released the second episode of its "Living with Netherton" video series, featuring the story of 79-year-old Norma Coles, who was diagnosed with Netherton Syndrome decades after her initial evaluation [1][2] - The campaign aims to raise awareness and support for individuals affected by Netherton Syndrome, highlighting the challenges faced by patients, including misdiagnosis and lack of treatment options [2][4] - Quoin's lead product candidate, QRX003, is currently undergoing clinical trials, with the goal of becoming the first FDA-approved treatment for Netherton Syndrome [5][6] Company Overview - Quoin Pharmaceuticals is a late clinical-stage specialty pharmaceutical company focused on developing treatments for rare and orphan diseases [1][7] - The company has a pipeline that includes four products targeting various rare conditions, including Netherton Syndrome, Peeling Skin Syndrome, and others [7] - Quoin is committed to addressing unmet medical needs and improving the quality of life for patients and their families [7] Product Development - QRX003 is a topical lotion designed to address the skin barrier issues associated with Netherton Syndrome by promoting a normalized skin-shedding process [6] - Initial data from ongoing clinical trials of QRX003 show promising results, including improvements in skin healing and reductions in inflammation and pruritus [5] - The company aims to complete the development of QRX003 to provide a transformative treatment option for patients who have long awaited effective therapies [5][6]